Article Information
History
- February 4, 2024.
Article Versions
- You are currently viewing Version 1 of this article (February 4, 2024 - 08:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sherry Masoud1,
- Katie Wong2,
- Lewis Downward3,
- David Pitcher4,
- Nicholas J.A. Webb5,
- Clare Proudfoot5,
- RaDaR Consortium6,
- Edwin K.S. Wong7 and
- Daniel P. Gale2,*
- 1National Registry of Rare Kidney Diseases, Bristol, United Kingdom
- 2University College London Department of Renal Medicine, London, United Kingdom
- 3Novartis Pharma AG, Basel, Switzerland
- 4National Registry of Rare Kidney Disease (RaDaR), Bristol, UK, Department of Renal Medicine, University College London, UK
- 5National Renal Complement Therapeutics Centre, Newcastle upon Tyne, United Kingdom
- 6-
- 7National Renal Complement Therapeutics Centre, Newcastle upon Tyne, UK
- ↵*Correspondence to:
Professor Daniel P Gale, UCL Department of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, d.gale{at}ucl.ac.uk.